Longitudinal studies of PTSD: Overview of findings and methods

Department of Psychiatry, Center for Traumatic Stress Studies, Hadassah University Hospital, Ein Kerem Campus, Jerusalem 91120, Israel.
CNS spectrums (Impact Factor: 1.3). 09/2006; 11(8):589-602.
Source: PubMed

ABSTRACT Posttraumatic stress disorder (PTSD) has a discernible starting point and typical course, hence the particular appropriateness of longitudinal research in this disorder. This review outlines the salient findings of longitudinal studies published between 1988 and 2004. Studies have evaluated risk factors and risk indicators of PTSD, the disorder's trajectory, comorbid disorders and the predictive role of acute stress disorder. More recent studies used advanced data analytic methods to explore the sequence of causation that leads to chronic PTSD. Advantages and limitations of longitudinal methods are discussed.

Download full-text


Available from: Arieh Y Shalev, Jul 05, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: a b s t r a c t There is broad interest in predicting the clinical course of mental disorders from early, multimodal clinical and biological information. Current computational models, however, constitute a significant barrier to realizing this goal. The early identification of trauma survivors at risk of post-traumatic stress disorder (PTSD) is plausible given the disorder's salient onset and the abundance of putative biological and clinical risk indicators. This work evaluates the ability of Machine Learning (ML) forecasting ap-proaches to identify and integrate a panel of unique predictive characteristics and determine their ac-curacy in forecasting non-remitting PTSD from information collected within10 days of a traumatic event. Data on event characteristics, emergency department observations, and early symptoms were collected in 957 trauma survivors, followed for fifteen months. An ML feature selection algorithm identified a set of predictors that rendered all others redundant. Support Vector Machines (SVMs) as well as other ML classification algorithms were used to evaluate the forecasting accuracy of i) ML selected features, ii) all available features without selection, and iii) Acute Stress Disorder (ASD) symptoms alone. SVM also compared the prediction of a) PTSD diagnostic status at 15 months to b) posterior probability of membership in an empirically derived non-remitting PTSD symptom trajectory. Results are expressed as mean Area Under Receiver Operating Characteristics Curve (AUC). The feature selection algorithm identified 16 predictors, present in !95% cross-validation trials. The accuracy of predicting non-remitting PTSD from that set (AUC ¼ .77) did not differ from predicting from all available information (AUC ¼ .78). Predicting from ASD symptoms was not better then chance (AUC ¼ .60). The prediction of PTSD status was less accurate than that of membership in a non-remitting trajectory (AUC ¼ .71). ML methods may fill a critical gap in forecasting PTSD. The ability to identify and integrate unique risk indicators makes this a promising approach for developing algorithms that infer probabilistic risk of chronic posttraumatic stress psychopathology based on complex sources of biological, psychological, and social information.
    Journal of Psychiatric Research 09/2014; 59. DOI:10.1016/j.jpsychires.2014.08.017 · 4.09 Impact Factor
  • Source
    Social Work in Mental Health 01/2014; 12:69-80. DOI:10.1080/15332985.2013.841611
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We report follow-up data evaluating the long-term outcomes for the first completed trial of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for chronic, treatment-resistant post-traumatic stress disorder (PTSD) (Mithoefer et al., 2011). All of the 19 subjects who received MDMA-assisted treatment in the original trial participated in the long-term follow-up (LTFU), with 16 out of 19 completing all of the long-term outcome measures, which were administered from 17 to 74 months after the original study's final MDMA session (mean = 45.4; SD = 17.3). Our primary outcome measure used was the Clinician-Administered PTSD Scale (CAPS). Secondary outcome measures were the Impact of Events Scale-Revised (IES-R) and the Neuroticism Extroversion Oppenness Personality Inventory-Revised (NEO PI-R) Personality Inventory. We also collected a long-term follow-up questionnaire. Results for the 16 CAPS completers showed there were no statistical differences between mean CAPS score at LTFU (mean = 23.7; SD = 22.8) (t(matched) = 0.1; df = 15, p = 0.91) and the mean CAPS score previously obtained at Study Exit (mean = 24.6, SD = 18.6). On average, subjects maintained statistically and clinically-significant gains in symptom relief, although two of these subjects did relapse. It was promising that we found the majority of these subjects with previously severe PTSD who were unresponsive to existing treatments had symptomatic relief provided by MDMA-assisted psychotherapy that persisted over time, with no subjects reporting harm from participation in the study.
    Journal of Psychopharmacology 11/2012; 27(1). DOI:10.1177/0269881112456611 · 2.81 Impact Factor